Erlotinib, lapatinib, afatinib, and neratinib all bind to EGFR and human epidermal growth factor receptor 2 (HER2), inhibiting downstream phosphorylation and angiogenesis, and are clinically used for NSCLC,142,143 pancreatic cancer,144 and breast cancer.145, 146, 147 Cabozantinib and regorafenib both target VEGFR, TIE2, c-KIT, and RET. Here, KDR is linked to breast carcinoma.